JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.

新泽西州新泽西市，2023年10月24日（GLOBE NEWSWIRE）-SCYNEXIS，Inc。（纳斯达克股票代码：SCYX），一家开创创新药物以克服和预防难治性和耐药性感染的生物技术公司，今天宣布介绍其第二代fungerp候选者SCY-247的临床前数据，针对广泛的真菌病原体。

The analyses were presented by Mahmoud Ghannoum, Ph.D, Professor and Director Center for Medical Mycology, Case Western Reserve University, in an oral presentation titled, “SCY-247, a Second-generation IV/Oral Triterpenoid Antifungal: In Vitro Activity Against a Broad-spectrum of Fungal Pathogens, and Dose-dependent Tissue Distribution In Vivo” at the 11th Congress on Trends in Medical Mycology (TIMM) held in Athens Greece October 20-23, 2023.

这些分析由凯斯西储大学医学真菌学教授兼主任Mahmoud Ghannoum博士在题为“，“SCY-247，第二代IV/口服三萜类抗真菌：对广谱真菌病原体的体外活性和体内剂量依赖性组织分布”，在雅典举行的第11届医学真菌学趋势大会（TIMM）希腊2023年10月20日至23日。

“We are excited to see the progress in the development of this novel compound from the fungerp family,” said Dr. Martin Hoenigl, FECMM, Associate Professor of Translational Mycology at University of Graz, Austria and president of the European Confederation of Medical Mycology (ECMM). “With the growing concern over antifungal resistance and the increase in the number of vulnerable patients susceptible to deadly fungal infections, there is an urgent need to address current gaps in our armamentarium with new therapies, particularly potent and broad-spectrum antifungals with oral and IV formulations and low risk for drug-drug interactions.” The preclinical study evaluated the activity of second-generation triterpenoid antifungal candidate SCY-247 against a range of fungal pathogens, including multi-drug resistant strains.

奥地利格拉茨大学转化真菌学副教授，欧洲医学真菌学联合会主席，FECMM的Martin Hoenigl博士说：“我们很高兴看到fungerp家族开发这种新型化合物的进展。”ECMM）。“随着对抗真菌药物耐药性的日益关注以及易受致命真菌感染影响的易感患者数量的增加，迫切需要解决目前我们医疗设备中存在的新疗法差距，特别是口服和静脉注射的强效和广谱抗真菌药物配方和药物相互作用的低风险。“临床前研究评估了第二代三萜类抗真菌候选物SCY-247对一系列真菌病原体（包括多药耐药菌株）的活性。

Results illustrated the potent and broad-spectrum in vitro activity of SCY-247, including against a large array of yeasts, molds and dimorphic fungi. Results.

结果说明了SCY-247的有效和广谱体外活性，包括针对大量酵母，霉菌和二态真菌。结果。